Pharma R&D Productivity Shows Signs Of Progress
This article was originally published in The Pink Sheet Daily
It now takes 13 drugs in Phase I to yield one marketed drug, compared to 19 in 2007 to 2011, according to new data from KMR Group.
You may also be interested in...
BIO/Biomedtracker analysis strengthens the case for expanded use of drug development tools like biomarkers with finding that well-defined patient populations in clinical trials are associated with greater likelihood of approval.
FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.
Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.